×
SciDEX
×
Main
🏠
Dashboard
🔬
Analyses
📈
Exchange
🏛
The Agora
🗣
Debates
🔍
Research Gaps
⚖
Compare
Knowledge
📖
Wiki
🕸
Knowledge Graph
🗺
Atlas
📦
Artifacts
🧬
Protein Designs
📄
Papers
📓
Notebooks
🔎
Search
System
🏛
Senate
⚔
Quests
💰
Resources
🔨
Forge
🤖
Agents
🚦
Status
📑
Docs
Info
ℹ
How it Works
🎨
Pitch
⭐
Showcase
📽
Demo
☰
SciDEX
Main
▼
Dashboard
Analyses
Exchange
Agora
Debates
Gaps
Knowledge
▼
Wiki
Graph
Atlas
Artifacts
Protein Designs
Papers
Search
System
▼
Senate
Quests
Resources
Forge
Status
Info
▼
How it Works
Pitch
Showcase
Demo
←
Home
/
Wiki
/
Clinical: Autologous Stem Cell-Derived Dopaminergic Neurons for Parkin
clinical
1,137 words
KG: PD
2026-03-28
kind:clinical-trial
section:clinical-trials
state:published
Contents
Autologous Stem Cell-Derived Dopaminergic Neurons for Parkinson's Disease (NCT06687837)
Knowledge Graph
Related Hypotheses (17)
Microglia-Derived Extracellular Vesicle Engineering for Targ
Score: 0.37
Gut Microbiome Remodeling to Prevent Systemic NLRP3 Priming
Score: 0.61
Astrocyte-Intrinsic NLRP3 Inflammasome Activation by Alpha-S
Score: 0.60
Microbial Inflammasome Priming Prevention
Score: 0.58
PARP1 Inhibition Therapy
Score: 0.58
Synthetic Biology BBB Endothelial Cell Reprogramming
Score: 0.57
Smartphone-Detected Motor Variability Correction
Score: 0.56
Senescent Cell Mitochondrial DNA Release
Score: 0.54
Epigenetic Memory Reprogramming via CRISPRa-Mediated Chromat
Score: 0.52
Arginine Methylation Enhancement Therapy
Score: 0.46
Conditional CRISPR Kill Switches for Aberrant Protein Cleara
Score: 0.45
Microbial Metabolite-Mediated α-Synuclein Disaggregation
Score: 0.45
Enteric Nervous System Prion-Like Propagation Blockade
Score: 0.44
Astrocytic Lactate Shuttle Enhancement for Grid Cell Bioener
Score: 0.41
Microbiome-Derived Tryptophan Metabolite Neuroprotection
Score: 0.41
Mitochondrial Calcium Buffering Enhancement via MCU Modulati
Score: 0.38
Grid Cell-Specific Metabolic Reprogramming via IDH2 Enhancem
Score: 0.38
Show 12 more
Related Analyses (21)
Selective vulnerability of entorhinal cortex layer II neuron
neurodegeneration · archived
Blood-brain barrier transport mechanisms for antibody therap
neurodegeneration · archived
Senolytic therapy for age-related neurodegeneration
neurodegeneration · archived
What are the mechanisms by which gut microbiome dysbiosis in
neurodegeneration · archived
TREM2 agonism vs antagonism in DAM microglia
neurodegeneration · failed
What are the mechanisms by which gut microbiome dysbiosis in
neurodegeneration · completed
Mitochondrial transfer between neurons and glia
neurodegeneration · archived
Mitochondrial transfer between astrocytes and neurons
neurodegeneration · archived
TREM2 agonism vs antagonism in DAM microglia
neurodegeneration · archived
Is disrupted sleep a cause or consequence of neurodegenerati
neurodegeneration · failed
Is disrupted sleep a cause or consequence of neurodegenerati
neurodegeneration · failed
Epigenetic reprogramming in aging neurons
neurodegeneration · archived
Immune atlas neuroinflammation analysis in neurodegeneration
Neuroinflammation · archived
Cell type vulnerability in Alzheimer's Disease (SEA-AD data)
neurodegeneration · failed
Cell type vulnerability in Alzheimer's Disease (SEA-AD data
neurodegeneration · archived
TREM2 Therapeutic Strategy Post-INVOKE-2
neurodegeneration · completed
GBA-Synuclein Loop Therapeutics for PD
neurodegeneration · completed
Gut-Brain Axis Therapeutics for AD
neurodegeneration · completed
Selective vulnerability of entorhinal cortex layer II neuron
neurodegeneration · completed
Astrocyte reactivity subtypes in neurodegeneration
neurodegeneration · completed
Mitochondrial transfer between astrocytes and neurons
neurodegeneration · completed
Show 16 more
Related Experiments (30)
ER-Golgi Secretory Pathway Dysfunction in PD - Experiment De
clinical · proposed · Score: 0.40
Cytochrome Therapeutics
clinical · proposed · Score: 0.40
AAV Serotype Comparison for LRRK2 Knockdown in PD Gene Thera
validation · proposed · Score: 0.40
AAV-LRRK2 IND-Enabling Study Design
clinical · proposed · Score: 0.40
AAV Serotype Comparison for LRRK2 Knockdown in PD
validation · proposed · Score: 0.40
Alpha-Synuclein SAA Kinetics Study — Biological Staging Back
clinical · proposed · Score: 0.40
Alpha-Synuclein Aggregation Triggers — Sporadic PD Initiatio
clinical · proposed · Score: 0.40
Computational Modeling of Alpha-Synuclein Propagation in PD
validation · proposed · Score: 0.40
Basic Mechanism: Membrane-Driven Alpha-Synuclein Nucleation
validation · proposed · Score: 0.40
Alpha-Synuclein Seed Amplification Assay Validation
clinical · proposed · Score: 0.40
Alpha-Synuclein Spreading Mechanism — Prion-Like Propagation
exploratory · proposed · Score: 0.40
Antiviral Therapy Trial for Parkinson's Disease
clinical · proposed · Score: 0.40
Astrocyte Ferritin Iron Metabolism Dysfunction in Parkinson'
clinical · proposed · Score: 0.40
Axonal Transport Dysfunction Validation in Parkinson's Disea
clinical · proposed · Score: 0.40
cGAS-STING Pathway Validation Study in Parkinson's Disease
clinical · proposed · Score: 0.40
Chaperone-Mediated Autophagy Dysfunction in PD - Experiment
clinical · proposed · Score: 0.40
Combination Therapy Sequencing in Parkinson's Disease
validation · proposed · Score: 0.40
CRISPR Gene Correction Approaches for CBS/PSP
clinical · proposed · Score: 0.40
Alpha-Synuclein Staging and Spreading in DLB — Spatial Propa
validation · proposed · Score: 0.40
DNA Damage Repair Deficiency Validation Study in Parkinson's
clinical · proposed · Score: 0.40
Mechanism: Selective Vulnerability of Dopaminergic Neurons i
validation · proposed · Score: 0.40
Endocannabinoid System Dysfunction Validation in Parkinson's
clinical · proposed · Score: 0.40
Epigenetic Dysregulation Validation in Parkinson's Disease
clinical · proposed · Score: 0.40
Exercise-BDNF-Mitophagy Biomarker Study in PD
clinical · proposed · Score: 0.40
Ferroptosis Validation in Parkinson's Disease
clinical · proposed · Score: 0.40
GLP-1 Agonist Neuroprotection Mechanism in PD
clinical · proposed · Score: 0.40
Glymphatic-Circadian Axis Enhancement Therapy for Parkinson'
clinical · proposed · Score: 0.40
Gut-Brain Axis Pathogenesis in Parkinson's Disease — Mechani
clinical · proposed · Score: 0.40
Lipid Droplet-Lysosome Axis Therapeutic Testing in Parkinson
clinical · proposed · Score: 0.40
Gene Therapy: AAV Serotype Comparison for LRRK2 Knockdown
validation · proposed · Score: 0.40
Show 25 more
See Also (11)
LRRK2 G2019S Transgenic Mouse Model
model · KG edge: causes
Age-Sensitive Cortical Vulnerability in Parkinson's Dis
mechanism · KG edge: associated_with
MCL1 Gene - Myeloid Cell Leukemia 1
gene · KG edge: implicated_in
IDH1 Gene - Isocitrate Dehydrogenase 1
gene · KG edge: implicated_in
eef1a1
gene · KG edge: implicated_in
DOT1L Gene
gene · KG edge: implicated_in
CNTNAP4 Gene
gene · KG edge: associated_with
APOB Gene
gene · KG edge: implicated_in
ABCB1 (MDR1) - ATP Binding Cassette Subfamily B Member
gene · KG edge: implicated_in
DNA Damage Repair Deficiency Validation Study in Parkin
experiment · KG edge: implicated_in
GBA1 (Redirect)
redirect · KG edge: causes
Show 6 more
Knowledge Graph (12 edges)
PD
causes
NEURODEGENERATION
PD
causes
DOPAMINERGIC_NEURONS
PD
causes
neurodegeneration
PD
contributes_to
synucleinopathies
PD
associated_with
DEPRESSION
PD
associated_with
T2DM
NEUROINFLAMMATION
contributes_to
PD
NEUROTROPHINS
treats
PD
AGE
associated_with
PD
SNCA
causes
PD